Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.

Kokolis S; Cavusoglu E; Clark LT; Marmur JD

首页> 外文期刊>Progress in Cardiovascular Diseases >Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.

【24h】

Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.

机译：接受经皮冠状动脉介入治疗的患者的抗凝策略：普通肝素，低分子量肝素和直接凝血酶抑制剂。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.

机译：低分子肝素和直接凝血酶抑制剂正在作为经皮冠状动脉介入治疗（PCI）的患者中普通肝素的替代抗凝剂。本文综述了这些新型抗栓剂的药理特性，并评估了临床数据，证明了它们在接受PCI的患者中的使用。

著录项

来源
《Progress in Cardiovascular Diseases》 |2004年第6期|共18页
作者
Kokolis S; Cavusoglu E; Clark LT; Marmur JD;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词
Angioplasty; Transluminal; Percutaneous Coronary; Anticoagulants; Fibrinolytic Agents; 血管成形术; 经腔; 经皮冠状动脉; 抗凝药; 纤维蛋白溶解药;

机译：Angioplasty;Transluminal;Percutaneous Coronary;Anticoagulants;Fibrinolytic Agents;血管成形术;经腔;经皮冠状动脉;抗凝药;纤维蛋白溶解药;

相似文献

外文文献
中文文献
专利

1. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. [J] . Kokolis S, Cavusoglu E, Clark LT, Progress in Cardiovascular Diseases . 2004,第6期

机译：接受经皮冠状动脉介入治疗的患者的抗凝策略：普通肝素，低分子量肝素和直接凝血酶抑制剂。
2. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study [J] . Ashok Seth Indian heart journal . 2015,第4期

机译：使用Bivalirudin，肝素加上糖蛋白IIB / IIIa抑制剂和未分支肝素单药治疗经皮冠状动脉干预的抗血栓形成策略的比较 - 单一中心观察研究
3. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the anti-thrombotic strategy for reduction of myocardial damage during angioplasty-bivalirudin vs heparin study) [J] . PattiG., PasceriV., DAntonioL., The American Journal of Cardiology . 2012,第4期

机译：比伐卢定与普通肝素在经皮冠状动脉介入治疗的高危患者中的安全性和有效性比较（来自在血管成形术中减少心肌损害的抗血栓策略-比伐卢定与肝素研究）
4. Influence of Diabetes Mellitus in patients with Long Coronary Lesions Undergoing Percutaneous Coronary Interventions: Multicenter PCI Registry in Japan [C] . E. Saito, M. Hirose, T. Miyauchi, International Congress on Coronary Artery Disease . 2003

机译：经皮冠状动脉干预患者糖尿病患者糖尿病的影响：日本多中心PCI登记处
5. The Association between Unfractionated Heparin and Bivalirudin Used during Percutaneous Coronary Intervention for Stable Angina and Acute Coronary Syndromes and the In-Hospital and Mortality Outcomes Observed across All Body Mass Index Groups [D] . Chen, Christine. 2021

机译：在所有体重指数群体中观察到稳定冠状动脉干预期间使用经皮冠状动脉介入和急性冠状动脉综合征的冠状动脉介入和医院和死亡率结果之间的联合肝素和Bivalirudin之间的关联
6. Comparison of anti-thrombotic strategies using Bivalirudin Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention – A single centre observational study [O] . Upendra Kaul, Ajay Dua, Arvind K. Sethi, 2015

机译：使用比伐卢定肝素加糖蛋白IIb / IIIa抑制剂和普通肝素单一疗法对经皮冠状动脉介入治疗患者的抗血栓形成策略的比较–单中心观察性研究
7. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. [O] . Li YJ, Rha SW, Chen KY, 2011

机译：低分子量肝素与普通肝素对急性ST段抬高型心肌梗死患者进行初次经皮冠状动脉介入治疗并使用药物洗脱支架的情况。

Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.

摘要

著录项

相似文献

相关主题

期刊订阅